Is NCT05696652 recruiting in Stanford, CA?

Yes, NCT05696652 is currently recruiting participants at its Stanford, CA location. This heart failure clinical trial is actively enrolling qualified participants.

How do I join the heart failure clinical trial in Stanford?

To join this clinical trial in Stanford, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Stanford clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Heart Failure Clinical Trial in Stanford, CA

About This Heart Failure Study in Stanford

The heart failure syndrome that occurs when the heart is too sick to properly do its job. One of the main symptoms is difficulty with exercise. One way to improve symptoms is to start patients in a 12 week exercise program called cardiac rehabilitation. Cardiac rehabilitation been shown to improve symptoms for heart failure patients. However, the investigators do not know exactly what exercise does to the molecules that make up the human body. If the investigators could answer this question, the investigators might find a whole new way to treat the symptoms of heart failure. Therefore the investigators want to know what molecules might be responsible for the benefits of exercise. The plan for this study is to measure the levels of thousands of proteins in blood samples which come from people with heart failure and see how those levels change after 12 weeks of cardiac rehabilitation, compared to the protein levels in patients whose cardiac rehabilitation is delayed until after the study period. If the investigators know the proteins that change with exercise, the investigators can then look to see if targeting these proteins with medicines can mimic the benefits of exercise. The long term goal of our work is to identify "exercise-in-a-pill" medicines that will help people with heart failure.

Sponsor: Stanford University

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form

Stated willingness to comply with all study procedures and availability for the duration of the study

Male or female, aged 18-89

Patients must carry a diagnosis of heart failure with ejection fraction \< 40%

Be willing to participate in cardiac rehabilitation, and not already done so in the last year

Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration

Must be able to exercise on a treadmill

Exclusion Criteria

Inability to complete CPET or participate in CR (verbal/chart)

Syncope during CPET within the last 6 mos, sustained VT on CPET, hemodynamically significant arrhythmia during CPET (verbal/chart)

BMI \>= 38 (verbal/chart)

History of a bleeding disorder or clotting abnormality (verbal/chart)

Clinical diagnosis of severe Chronic Obstructive Pulmonary Disease (COPD) (verbal/chart)

History of malignancy not considered in remission (verbal/chart)

Cirrhosis (verbal/chart)

Thyroid disease (verbal/chart)

Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory within the last 1 year

Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting

Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment

Cancer (verbal/chart)

History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years

Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months

Chronic active or latent infection (verbal/chart)

Active or latent infections requiring chronic antibiotic or anti-viral treatment

Chronic active infection whether on chronic antimicrobials or not

Human Immunodeficiency Virus

Active hepatitis B or C undergoing antiviral therapy

Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded

Tobacco (verbal/chart)

Current smokers: any tobacco or e-cigarette/e-nicotine products

Former smokers: Stopped smoking \<6 months at time of screening

Not be pregnant or lactating in the last 12 months, or planning to become pregnant for the next 4 months. Not be post-partum during the last 12 months. (verbal/chart)

Metabolic bone disease (self-report): History of non-traumatic fracture from a standing height or less. Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen. (verbal/chart)

Diabetes (self-report and screening), which includes: i) treatment with any insulin or ii) A1c \>=8.0 (screening). (verbal/chart)

Chronic renal insufficiency (screening): estimated glomerular filtration rate \<30 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation. (verbal/chart)

Individuals receiving any active treatment for autoimmune disorders (including monoclonal antibodies) within the last 6 months. (verbal/chart)

Alcohol consumption: i) more than 7 drinks per week for women and more than 14 drinks per week for men; ii) history of binge drinking. (verbal/chart)

Any individual engaging in night shift work in the last 6 months.

Hospitalization for any psychiatric condition within one year (verbal/chart)

Any musculoskeletal or ligamentous injury, amputation or congenital neurological defect that, in the opinion of the team clinician, would negatively impact or mitigate participation in and completion of the protocol. (verbal/chart)

Mental incapacity and/or cognitive impairment on the part of the participant that would inhibit adequate understanding of or cooperation with the study protocol

Other (clinician judgment)

Genetic metabolic disorders that could affect metabolomic results (e.g., phenylketonuria)

Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol

Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol

Medication exclusions (chart review)

Androgenic anabolic steroids, antiestrogens, antiandrogens

Growth hormone, insulin like growth factor, growth hormone releasing hormone

Insulin of any type used regularly

Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise induced muscle hypertrophy

Psychiatric

Chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines; short-acting non-benzodiazepine sedative-hypnotics are allowed

Two or more drugs for depression

Mood stabilizers

Antiepileptic drugs

Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs

Anti-psychotic drugs

Narcotics and narcotic receptor agonists

Chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc) for any reason

High-potency topical steroids if ≥10% of surface area using rule of 9s

Continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention

Monoclonal antibodies

Anti-rejection medications/immune suppressants

Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Stanford?

Yes, this clinical trial (NCT05696652) has an active research site in Stanford, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure Treatment Options in Stanford, CA

If you're searching for heart failure treatment options in Stanford, CA, this clinical trial (NCT05696652) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure clinical trials near you to find additional studies recruiting in your area.

Heart Failure Clinical Trial in Stanford, CA

Expert Care in Stanford

IRB Approved

No-Cost Care

Apply for This Stanford Location

Why Participate?

Simple Process